Company profile
BIOAGE LABS, INC.
NASDAQ:BIOABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ASAPIPRANT | phase2 | — | 2 | terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07656727 | phase2 | active_not_recruiting | 2026-06-11 | 2026-11-30 | BioAge Labs, Inc. | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors |
| NCT07812090 | phase2 | recruiting | 2026-08-21 | 2027-11-01 | BioAge Labs, Inc. | A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema |
| NCT06515418 | phase2 | terminated | 2024-06-27 | 2025-02-06 | BioAge Labs, Inc. | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over |
| NCT06141889 | phase1 | completed | 2023-11-17 | 2024-01-26 | BioAge Labs, Inc. | Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers |
| NCT05152641 | phase2 | withdrawn | 2022-04-01 | 2023-04-01 | BioAge Labs, Inc. | Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery |
FDA applications (0)
No records yet.